Publications by authors named "David J Propper"

Claim this Profile
P
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
David J Propper, Fangfei Gao, Mark P Saunders, Debashis Sarker, John A Hartley

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing cytokines and chemokines for cancer therapy.
David J Propper, Frances R Balkwill

Nat Rev Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.
Hemant M Kocher, Bristi Basu, Fieke E M Froeling, Debashis Sarker, Sarah Slater, David J Propper

Nat Commun· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.
Wai M Liu, Sandra J Strauss, Tracy Chaplin, Sipra Shahin, David J Propper

Hematol J· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Wai M Liu, Katherine A Scott, Sipra Shahin, David J Propper

Eur J Biochem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
David J Propper, David Chao, Jeremy P Braybrooke, Pru Bahl, Parames Thavasu

Clin Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis